- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07605091
RELIANCE: Moringa in Lactation and Early Childhood
This study will assess the impact of maternal moringa supplementation to mothers of breastfeeding infants on milk output, milk composition, exclusive breastfeeding duration, and maternal and child health. This will be accomplish by conducting a randomized, controlled dietary intervention study enrolling breastfeeding mothers and their newborn infants. Mothers will be randomized to receive either 10g dried moringa leaf powder in carrier vs. carrier alone, consumed daily for four months, with follow-up for 2 years.
Women must be >18 years of age, ≤ 21 days postpartum and currently lactating at the time of enrollment. Infants must be at least 37 weeks of gestational age, be healthy and are able to feed orally and consume human milk.
After randomization and enrollment, breast milk samples will be obtained at baseline, 2, 4, 6, 9 and 12 months. Serum from mothers will be collected at recruitment, 2, 4, 6,and 12 months; infant serum will be collected by capillary sample at recruitment and approximately at 2, 6, 12, and 24 months. Infant feeding weights (test weights) will be collected on sequential days at recruitment, 4, and 6 months.
Dietary recall: the foods and drinks consumed by mothers in the past month prior to each milk sample.
Other assessments will include perceptions of breastfeeding, assess complementary feeding practices. Review will be conducted of maternal and infant infections, diagnoses, and hospitalizations at the time of visit or since the last visit.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Introduction: The objective of the proposed study is to assess the impact of maternal moringa supplementation to mothers of breastfeeding infants on milk output, milk composition, exclusive breastfeeding duration, and maternal and child health. This will be accomplished by conducting a randomized, controlled, dietary intervention study enrolling 100 breastfeeding mothers and their newborn infants with four months intervention and two years follow up. The propose design is for a study of 10g dried moringa leaf powder in carrier vs. carrier alone, consumed daily for four months by breastfeeding mothers of term infants. The investigators will continue the intervention for four months and follow-up for 2 years.
Inclusion Criteria: Women must be >18 years of age; ≤ 21 days postpartum and currently lactating at the time of enrollment. Infants must be at least 36 weeks gestational age at birth, singleton birth, exclusively breastfeeding at the time of enrollment.
Exclusion Criteria: Women who report regular consumption of moringa in the last month (>1 time weekly) or are unable unwilling to lactate are ineligible to participate in this study. Infants are ineligible if born before 37 weeks of gestational age, have significant congenital disease, are unable to feed orally, or unable to consume human milk.
Overall Design: A randomized, controlled dietary intervention trial, titled The MiLC Study: Moringa in Lactation and Early Childhood.
Recruitment and Retention: Potential study participants will be identified on arrival to their first postnatal visit to the SUNY Downstate Maternal and Child Health Clinics. All eligible participants will be offered enrollment. Participants will be screened by trained research assistants and enrolled into the study with individual or caregiver informed consent and monthly check-ins. Participant follow-up will occur concurrent with pediatric monitoring visits (approximately 2, 4, 6, 9, 12, 15, 18, 24 months) for two years utilizing study staff and study equipment. Follow-up not requiring in-person visits or participants who do not arrive to their scheduled study visit will receive phone call/text communication to obtain study information and to reschedule follow-up.
Randomization: Upon enrollment, participants will be randomized to the intervention group and the control. All members of the study team will be blinded to this assignment until all primary outcomes are analyzed.
Intervention and control: Intervention and control that are validated through an acceptability trial and subsequently through the investigators pilot clinical trial. Moringa leaf powder at 10g/day was deemed acceptable by mothers previously. The most palatable combination will be utilized for the trial. The control group will receive carrier alone. Moringa at this dose and higher has been used in multiple clinical trials including the investigator's own pilot with no known adverse effects; these are summarized in the systematic review. The investigators think that the carrier alone is the best control for this study. All subjects will be consuming a palatable carrier of approximately equal calories.
Sample collection: The investigators will obtain breast milk samples (~5ml/timepoint) at baseline, 2, 4, 6, 9 and 12 months in a light-protected manner, as retinols and carotenoids are light-sensitive. The investigators will follow protocols piloted in the prior clinical trial. Women will be asked with study staff supervision to perform expression of the whole breast standardized to the early morning. This will occur outside of direct sunlight, and milk samples will be swirled and aliquoted by study staff then stored on dry ice until transport, where they will be stored at -80C. Serum from mothers will be collected at recruitment, 2, 4, 6,and 12 months; infant serum will be collected by capillary sample at recruitment, 2, 6, 12 and 24 months. Infant hemoglobin will be assessed as per usual clinical protocol at 12 months. 24-hour pre- and post-infant feeding weights (test weights) will be collected on sequential days at recruitment, 4, and 6 months. Investigators will provide a validated scale and clear instructions on weights, and request photographic documentation of weight.
Test weights: Test weights will be performed by weights on provided digital scales in the same clothing or consistently naked before and after each feed. This will occur over a standardized 24 hour period at each collection timepoint. Mothers will record the weights in a parent diary and send photos of the weights to the study team.
Dietary recall: Investigators will review the foods and drinks consumed by mothers in the past month prior to each milk sample.
Perceptions of breastfeeding survey and additional information: At each follow-up, the investigators will do the following: • administer a short, structured questionnaire to mothers to assess their perceptions of infant satiety, adequacy of milk production, and concerns about their provision of milk to their infant.
- assess complementary feeding practices (introduction of anything that is not prescribed medication to the infant)
- review of maternal and infant infections, diagnoses, and hospitalizations at the time of visit or since the last visit.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Philip Kern
- Telefonní číslo: 8593232615
- E-mail: pake222@uky.edu
Studijní místa
-
-
New York
-
Brooklyn, New York, Spojené státy, 11203
- SUNDY Downstate
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Mothers: Inclusion criteria - >18 years of age, s/p delivery of a healthy infant, and planning breast feeding.
- Infants: must be born at term (=37-42 weeks), singleton birth, lactating, age 7-21 days at enrollment
Exclusion Criteria:
- Mothers - women reporting regular consumption of moringa in the last month (>1 time weekly), unable to consume moringa or unable to complete study activities within the first two weeks.
- Mothers - Women with a contraindication to Moringa use (blood thinners, levothyroxine, antihypertensive treatments, insulin dependency).
- Infants - significant congenital disease, are unable to feed orally.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Carrier and Moringa Leaf Powder
|
Participants randomized to Moringa will consume 10 grams each day of the Moringa leaf powder mixed into porridge.
|
|
Komparátor placeba: Carrier
|
Participants randomized to the control will be given porridge without Moringa.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Human Milk Production (milk volume)
Časové okno: Baseline, 2 months, 4 months, 6 months, 9 months and 12 months
|
Human milk production measured by 24-hour infant test-weighing to estimate daily milk volume.
|
Baseline, 2 months, 4 months, 6 months, 9 months and 12 months
|
|
Duration of Exclusive Breastfeeding
Časové okno: Up to 12 months
|
Duration of exclusive breastfeeding assessed by maternal report.
|
Up to 12 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Maternal Serum Levels of Estradiol
Časové okno: Baseline, 2 months, 4 months, 6 months and 12 months
|
Maternal serum estradiol concentration measured from blood samples to assess hormonal changes associated with lactation following moringa supplementation compared with placebo.
|
Baseline, 2 months, 4 months, 6 months and 12 months
|
|
Maternal Serum Levels of Progesterone
Časové okno: Baseline, 2 months, 4 months, 6 months, and 12 months
|
Maternal serum progesterone concentration measured from blood samples to assess hormonal changes associated with lactation following moringa supplementation compared with placebo
|
Baseline, 2 months, 4 months, 6 months, and 12 months
|
|
Maternal Serum Levels of Prolactin
Časové okno: Baseline, 2 months, 4 months, 6 months, and 12 months
|
Maternal serum prolactin concentration measured from blood samples to assess hormonal changes associated with lactation following moringa supplementation compared with placebo
|
Baseline, 2 months, 4 months, 6 months, and 12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 108194
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Kojení
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital a další spolupracovníciDokončenoPrůvodce klinickou aplikací Conebeam Breast CTČína
-
Xijing HospitalAktivní, ne náborRakovina prsu | Rakovina prsu (Triple Negative Breast Cancer (TNBC))Čína
-
Assistance Publique - Hôpitaux de ParisZatím nenabírámeRakovina prsu (Triple Negative Breast Cancer (TNBC))
-
Shanghai Henlius BiotechZatím nenabírámeRakovina prsu (Triple Negative Breast Cancer (TNBC))Čína
-
Gangnam Severance HospitalNáborHER2 Enriched Subtype Cancer Breast, Herzuma, PAM50 StudyKorejská republika
-
BioNTech SESeventh Framework ProgrammeDokončenoRakovina prsu (Triple Negative Breast Cancer (TNBC))Švédsko, Německo
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH); Rising...NáborAnatomický karcinom prsu stadia II AJCC v8 | Anatomický karcinom prsu stadia III AJCC v8 | Rané stadium karcinomu prsu | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Spojené státy
-
Emory UniversityNational Cancer Institute (NCI)StaženoPrognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v mozku | Metastatický karcinom prsu | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)DokončenoAnatomický karcinom prsu stadia IV AJCC v8 | Prognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v kosti | Metastatický maligní novotvar v lymfatických uzlinách | Metastatický maligní novotvar v játrech | Metastatický karcinom prsu | Metastatický maligní novotvar v plicích | Metastatický... a další podmínkySpojené státy, Kanada, Saudská arábie, Jižní Korea
-
Jessica Mezzanotte SharpeNáborNemalobuněčný karcinom plic | Klasický Hodgkinův lymfom | Spinocelulární karcinom v ústech | Melanom (rakovina kůže) | Rakovina prsu (Triple Negative Breast Cancer (TNBC)) | Invazivní karcinom prsu | Renální buněčný karcinom (rakovina ledvin) | Rakovina konečníku s MSI-H/dMMRSpojené státy
Klinické studie na Moringa Leaf Powder
-
Institut de cancérologie Strasbourg EuropeLEAF4Life, Inc.DokončenoSyndrom akutní dechové tísně | COVID19, sepse nebo jiné příčinyFrancie
-
WomedDokončenoIntrauterinní adhezeBelgie, Francie, Holandsko
-
WomedAktivní, ne náborAshermanův syndrom | Intrauterinní adhezeŠvýcarsko, Španělsko, Francie, Čína, Belgie, Česko, Itálie
-
Ziauddin HospitalZápis na pozvánkuHorečka dengue | Pediatričtí pacienti | Extrakt z listů papájaPákistán
-
Shanghai Golden Leaf MedTec Co. LtdNeznámý
-
Natural Immune Systems IncZatím nenabíráme
-
Remko P. BosgraafDokončenoAshermanův syndrom | Intrauterinní adhezeHolandsko
-
University of California, San FranciscoDokončeno
-
Cheng LeiZatím nenabíráme
-
Northwestern UniversityUniversity of California, San FranciscoDokončeno